The Turenne Santé team has over EUR 120 million at its disposal to invest in the entire value chain of healthcare companies through various investment approaches:
– Expansion / buyout capital;
– Venture capital.
Turenne Santé also runs the Fondation pour l’Innovation Thérapeutique Béatrice Denys (Foundation Beatrice Denys for Therapeutic Innovation), which rewards the most successful projects within the French academic research, under the aegis of the Fondation pour la Recherche Médicale (Medical Research Foundation).
General Partner, Turenne Santé
Mounia joined Turenne Capital in 2013. Mounia has been managing the healthcare division with Benoit Pastour since the beginning of 2015.
Mounia has over 15 years’ experience in corporate finance in the healthcare sector in France and abroad. Prior to joining Turenne Capital, Mounia led Inserm Transfert Initiative, a start-up fund specialised in Healthcare, and was Partner responsible for Healthcare investments at Ventech (Groupe Natexis et Banques Populaires) and, prior to that, Atlas Venture. In particular she led several investments, trade sales and IPOs on NASDAQ and Euronext, including Biovex (sold to Amgen for USD 1 billion), Cellerix, which is listed on Euronext as TIG, and Scynexis, listed on NASDAQ. Mounia Chaoui has also advised investment funds and companies on raising equity in the Healthcare sector at Altran Technologies.
Within Turenne Capital, Mounia is responsible for JRI, Didactic and Dial Invest via the Capital Santé I fund, and Alizé Pharma, Eyetechcare at Horama via Sham Innovation Santé.
Mounia Chaoui is a graduate of Ecole Centrale (Paris) and has a PhD in Molecular Biophysics (Paris VI/Institut Gustave Roussy, CNRS).
Senior Associate - Lyon
Before joining Turenne Capital in 2014, Bervin Bouani spent six years as an Asset Manager within the investment department at SHAM, an insurer specialised in healthcare companies’ risks. At SHAM, Bervin was in charge of risky assets (listed equities, alternative management and private equity) and in particular was involved in the development of the private equity business (EUR 30 million invested in 15 companies, including Adocia). Bervin began his career as a junior financial engineer at CM-CIC.
Bervin holds a Master’s degree in Markets and Corporate Finance from Université Catholique de Lille.
Bervin is responsible for the Nutrionix, Cytoo, Brainever and Orega Biotech holdings.
Associate - Paris
Before joining Turenne Capital in 2016, for three years Grégory Dupas was Associate at Développement & Partenariat, a multi-sector investment fund working with SMEs.
Gregory started his career with an M&A experience at Groupe Bel.
At Turenne Capital his role includes analysing investment opportunities for the Capital Santé I Fund.
Grégory holds an MSc from EM Lyon, is a graduate of HEC Montréal and has a degree in Accounting and Management (DCG).
Mehdi joined Turenne Capital at the end of 2015, after spending six months at CM-CIC Innovation.
His responsibilities include analysing investment opportunities for the Sham Innovation Santé Fund.
Mehdi holds a PhD in Pharmacy (Faculté de Pharmacie Rennes 1) and is a graduate of ESCP Europe (MS Management Biopharmaceutique).
Après une première expérience chez PwC comme auditeur financier, suivie d’une expérience en tant qu’analyste au sein du fonds de dette mezzanine ActoMezz, Camille intègre le groupe Turenne Capital en 2017 en tant qu’Analyste Private Equity au sein de l’équipe santé et multisectorielle.
Camille est diplômée du Magistère Banque Finance et Assurance de l’Université Paris Dauphine, avec une spécialisation en finance d’entreprise.
Expansion / buyout capital
FPCI Capital Santé I
The Capital Santé I Professional Private Equity fund (FPCI) is a growth driver that operates through individual or combined expansion and buyout capital operations. Each deal is specifically addressed with a “Sur Mesure“ Appoach according to its Business characteristics and challenges.
This vehicle invests primarily in profitable French companies with a proven business model.
We support companies in the Healthcare sector with an enterprise value usually within the EUR 10-to-100-million bracket.
Moreover, we see it as essential that we share common interests and objectives with the management teams.
Our involvement consists in acquiring non-controlling or controlling stakes through investments between EUR 2 and 15 million.
Co-investment is possible alongside Altur Investissement and Nord Capital, and third party Capital providers.
A SPECIFIC THEMED APPROACH
The fund targets, inter alia, companies that:
- Manufacture and/or distribute medical equipment, diagnostic kits, nutraceuticals or medicines;
- Are suppliers or subcontractors to Healthcare manufacturers and service, advice and products providers;
- Offer healthcare solutions by creating networks or gathering institutions;
- Develop IT tools and software for Healthcare providers;
- Develop better organisation of care and treatment of patients;
- Publish information, especially through training, the internet and the press.
A COMMITTED INVESTMENT COMMITTEE WORKING WITH US
Composed of our main investors and two Healthcare sector experts:
|Hubert Olivier :
– Chairman of the Management Board of Groupe OCP,
– Former Chairman of Teva
– Ecole de Commerce du Havre – INSEAD
Albert Saporta :
– Chairman, Groupe Stallergenes
– International operations manager, Pasteur Mérieux Connaught
– Graduate of ESSEC – Harvard
Sham Innovation Santé
Launched in July 2014, Sham Innovation Santé is an evergreen Venture Capital Fund advised by Turenne Capital that invests in venture capital in biotech and medtech companies. Sham, a major Mutual Insurance Company based in Lyon, is the Fund sponsor.
Sham Innovation Santé invests into companies that are developing breakthrough technologies in the medical and Biotechnology fields. The portfolio – 12 companies – is being gradually built up by new investments in the healthcare and life sciences field, with a target of EUR 50 million.
The Sefti fund was set up in 2005 by Béatrice Denys and Eric Viaud at SGAM (now Amundi). Sefti 1 (Specialized European Fund for Therapeutic Innovation) is an investment fund with EUR 20.5 million invested in companies that are developing major therapeutic innovations. Turenne Capital took over the management of the fund’s holding in July 2011.
Sefti 1 focuses mainly on cardiovascular, oncological and immunological specialities. With money raised from institutional, industrial and Family Office investors, the Sefti fund is fully invested in four companies derived from academic research and is not planning to make any new investments.
The « Fondation pour l’Innovation Thérapeutique Béatrice Denys »
Turenne Santé also runs the Béatrice Denys Foundation for Therapeutic Innovation, which rewards the most successful projects within French academic research, with the aim of starting a company, under the aegis of the Fondation pour la Recherche Médicale (Medical Research Foundation).
Béatrice Denys was a doctor, and a graduate of ESSEC.
Although she began her career in the pharmaceutical industry, she rapidly moved into investment in the field of Healthcare, joining SGAM (now Amundi PEF) in 2000. In December 2005 she set up and subsequently managed the SEFTI (Specialized European fund for therapeutic innovation) FCPR, a venture capital fund of EUR 20 million raised from US medication manufacturers and institutional and retail investors. Sefti invested in companies developing breakthrough technologies in the biotech, diagnostics and medical device fields.
She joined Turenne Capital as Managing Partner of the Healthcare Division in 2011, where she played a role in launching Turenne Santé’s business.
Béatrice died in December 2012. The Medical Research Foundation and Turenne Capital Partenaires paid tribute to her by renaming the Therapeutic Innovation Foundation, which she had herself set up, the Béatrice Denys Foundation for Therapeutic Innovation.
Make a donation!
The Béatrice Denys Foundation for Therapeutic Innovation is supported by Turenne Capital, healthcare manufacturers and numerous individual donors. It aims to sustain and develop its activities by welcoming new donors.
We would like to thank the Fondation pour la Recherche Médicale for handling the administrative and accounting management of donations.
A tax receipt will be given to each donator.
Donations entitle the donor to French tax relief on part of the donation.
For a company: 60%, within the limit of 5/1000ths of pre-tax turnover,
For an individual:
- Income tax: 66%, within the limit of 20% of taxable income
- Wealth tax: 75%, up to a maximum of EUR 50,000
For further information please contact: firstname.lastname@example.org or on + 33 1 53 43 03 03.
Call for projects
In September this year, the Béatrice Denys Foundation for Therapeutic Innovation launched its 2016-2017 call for projects in support of company startup creations derived from biomedical academic research.
The aim is to support one or more cutting-edge scientific projects within French academic biomedical research through subsidies of up to fifty thousand euros (EUR 50,000).
The winners will be announced in May 2017.
Contact: email@example.com / +33 1 53 43 03 03
|2017||Stéphane Delliaux (Medical Doctor, PhD) and Rachid Bouchakour (Professor)
Development of a personal assistant preventing heart blocks or arrhythmias (rhythm disturbance)
(PhD Institut Pasteur, MBA ESCP)
Development of a class of molecules able to regenerate healthy tissues (especially muscle tissues).
|2016||Bruno Vénuat & Alain Thierry
CHU Montpellier (teaching hospital)
Development of an innovative blood-test based oncological diagnostic test (analysis of circulating DNA)
CHU Saint-Etienne (teaching hospital)
Development of an innovative beating-heart annuloplasty method for severe mitral insufficiency
|Discovery of new therapeutic targets for treating neuropathic pain.|
Institut Langevin, Paris
|Development of a ground-breaking ultrasound therapy for focused treatment of heart valve conditions|
Hôpital européen Georges Pompidou, Paris (INSERM)
|New concept for treating severe ischemia in the lower limbs of diabetic patients using cell therapy|
Université Denis Diderot Paris 7 and AP-HP
|Validation and use of the properties of fucoidan to target different therapeutic or diagnostic agents in atheroma plaques|
|Pr. Denis Vivien
Université de Caen
|Development of thrombolytics prescribed for treating stroke, presenting less side effects that products currently in use|
Université Denis Diderot Paris
|Development of an antithrombotic humanized recombinant antibody|
Hôpital de la Pitié-Salpêtrière, Paris
|Pharmaco-genetic pangenomic exploration of the response to thienopyridine-type platelet anti-coagulants: secondary study to the ARTIC study|
Collège de France, Paris
|Development of an apelin receptor antagonist as a potential treatment for cardiac insufficiency|
Université de Rouen
|Specialised therapeutic angiogenesis project for treating chronic cardiac insufficiency|
Université Sophia Antipolis, Nice
|Project targeting the mechano-sensitive ion channels in the cardiovascular system: development of new pharmacological targets for the treatment of atrial fibrillation and high blood pressure|
|Test for measuring resistance to oxidation|
Université Paris Sud 11, Orsay
|Development of an antidote from heparin derivatives|
Université Pierre et Marie Curie, Paris 6
|Development of a fluid-based microsystem for measuring “APOL” platelet aggregation|
|Oliver Romain & Pascal Leprince
Université Pierre et Marie Curie Paris 6, Université de Cergy Pontoise
|Design for an intelligent endoprosthesis for intelligent monitoring of aneurisms of the abdominal aorta (ENDOCOM)|